Selective ACC inhibitors currently under development for combination therapy demonstrate substantial improvements in the reduction of MASLD activity, liver steatosis, lobular inflammation, hepatocellular ballooning, and liver biochemistry [150] Clesacostat (2–50 mg/d) exhibited effectiveness in reducing liver steatosis and is being developed in conjunction with the DGAT2 inhibitor ervogastat to address the rise in serum TAG associated with ACC inhibitors. The gene discussed is DGAT2; the disease is fatty liver disease.